Addex Therapeutics (ADXN) Cash & Current Investments (2022 - 2024)
Addex Therapeutics' Cash & Current Investments history spans 3 years, with the latest figure at $3.8 million for Q4 2024.
- For Q4 2024, Cash & Current Investments fell 12.48% year-over-year to $3.8 million; the TTM value through Dec 2024 reached $3.8 million, down 12.48%, while the annual FY2024 figure was $3.8 million, 11.76% down from the prior year.
- Cash & Current Investments for Q4 2024 was $3.8 million at Addex Therapeutics, down from $4.4 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $7.2 million in Q4 2022 and bottomed at $3.8 million in Q4 2024.
- The 3-year median for Cash & Current Investments is $4.4 million (2023), against an average of $5.1 million.
- The largest annual shift saw Cash & Current Investments crashed 39.64% in 2023 before it decreased 12.48% in 2024.
- A 3-year view of Cash & Current Investments shows it stood at $7.2 million in 2022, then plummeted by 39.64% to $4.4 million in 2023, then dropped by 12.48% to $3.8 million in 2024.
- Per Business Quant, the three most recent readings for ADXN's Cash & Current Investments are $3.8 million (Q4 2024), $4.4 million (Q4 2023), and $7.2 million (Q4 2022).